1316755-17-5

1316755-17-5 structure

Name: EMA401 sodium
Chemical Name: Sodium (3S)-5-(benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate
CAS Number: 1316755-17-5
Molecular Formula: C₃₂H₂₈NNaO₅
Molecular Weight: 529.56
Catalog: Signaling Pathways GPCR/G Protein Angiotensin Receptor
Create Date: 2021-01-08 17:34:46
Modify Date: 2024-01-07 23:14:10
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].

Name	Sodium (3S)-5-(benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate
Synonyms	3-Isoquinolinecarboxylic acid, 2-(2,2-diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-, sodium salt, (3S)- (1:1) Sodium (3S)-5-(benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate MFCD30502664

Description	Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].
Related Catalog	Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor Research Areas >> Neurological Disease
Target	"Reverse Transcriptase[1] HIV[1]"
In Vivo	EMA401 sodium（10mg/kg；口服）导致慢性压迫性损伤 (CCI) 后第 14 天大鼠的 θ 功率显着减弱和缩爪潜伏期 (PWL) 增加[4]。
References	[1]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.Lancet. 2014 May 10;383(9929):1637-47. [2]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38. [3]. Suguru Koyama,et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.